Loading clinical trials...

ENROLLING_BY_INVITATIONNA

IVC and Lung Ultrasound B-lines Guided Decongestion in Critically Ill ESKD Patients With Heart Failure

Inferior Vena Cava and Lung Ultrasound B-lines Guided Decongestion in Critically Ill Kidney Failure Patients With Heart Failure: a Single-center, Prospective, Randomized Controlled Intervention Study

NCT06373575•The First Affiliated Hospital with Nanjing Medical University

View on ClinicalTrials.gov

Summary

The objectives of this trial are to determine whether, in critically ill ESKD patients randomization to fluid removal guided by lung and inferior vena cava ultrasound, compared to standard care, leads to Improved pulmonary congestion (primary outcome); and safety (secondary outcome) in the short-term.

Detailed Description

The point-of-care ultrasound was thought useful in the management of fluid in critically ill patients. At present, the role of the lung and inferior vena cava ultrasound is unclear in the management of decongestion of heart failure in kidney failure (KF) patients using prolonged hemodialysis. The investigators aim to explore the effect of pre-dialysis probing with the lung and inferior vena cava to guide fluid removal as compared with conventional protocols on the improvement of heart failure symptoms in patients with KF with heart failure under prolonged hemodialysis in the short-term.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. patients meet the diagnostic criteria for end-stage renal disease;
•2. indications that the patient may be experiencing signs and/or symptoms of heart failure, and based on the serum N-terminal pro-brain natriuretic peptide level of greater than 11,215. 2 ng/L;
•3. patients may require prolonged intermittent renal replacement therapy due to volume overload;
•4. patients ≥18 yo and ≤80 yo;
•5. either the patient or a family member signs the informed consent;
•6. patients will undergo at least two sessions of prolonged hemodialysis.

Exclusion Criteria

•1. history of malignancy or psychiatric disease;
•2. patients with a history of congenital heart disease or hypertrophic cardiomyopathy;
•3. coagulation abnormalities, intracranial, visceral or gastrointestinal bleeding in the past 3 months, or contraindications to heparin anticoagulation;
•4. The duration of prolonged hemodialysis \<8 hours;
•5. Ultrasound unable to monitor the inferior vena cava, or can't access the date;
•6. Pregnancy;
•7. Patients with severe respiratory failure;
•8. Patients with combined severe infections, such as patients with sepsis;
•9. Presence of pre-dialysis hypotension: systolic blood pressure \<90 mmHg;
•10. other conditions deemed ineligible by physicians.

Locations (1)

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Key Dates

Start Date

May 1, 2024

Primary Completion Date

April 30, 2025

Completion Date

June 30, 2025

Last Updated

April 18, 2024

Enrollment

ESTIMATED participants

Conditions

End-stage Renal Disease

Interventions

Lung and inferior vena cava ultrasound guidance

PROCEDURE

Conventional protocol guidance

PROCEDURE

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

NCT04634916

Kidney Disease, End-StageEnd-stage Renal Disease+1 more

View study

RECRUITINGPHASE3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472

HyperphosphatemiaChronic Kidney Disease, Receiving Dialysis+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

IVC and Lung Ultrasound B-lines Guided Decongestion in Critically Ill ESKD Patients With Heart Failure

Inclusion Criteria

Exclusion Criteria

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension

Comparative Study of Prognosis and QOL Between APD-RPM and CAPD

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant